Considering the neuroendocrine features of SCLC and Merkel cell carcinoma (MCC), this article evaluates DLL3 expression, its association with common clinicopathological factors, and its …

Purpose: Delta-like protein 3 (DLL3) is being developed as a predictive biomarker for DLL3-targeting antibody-drug conjugate and other therapies. Given the neuroendocrine features of …

Delta‐like canonical Notch ligand 3 (DLL3) is a member of the Delta/Serrate/Lag2 (DSL) Notch receptor ligand family and plays a crucial role in Notch signaling, which influences various …

Oct 4, 2019 · We found that DLL3 expression was seen in 51 of 56 (91%) from MCC samples (DLL3-high, 33 samples and DLL3-low, 18 samples) . Of the matched primary and metastatic …

Dec 1, 2024 · Delta-like ligand 3 (DLL3), an inhibitory ligand of Notch receptor, has emerged as a potential target for novel diagnostic and therapeutic strategies in NENs, since overexpression …

Delta-like ligand 3 (DLL3) is overexpressed in many NENs, implicated in tumor progression, and associated with poor clinical outcomes, especially in patients with NEC. DLL3-targeting …

Nov 8, 2024 · DLL3-TOPAbody effectively targets DLL3-expressing tumors, inducing cytokine release, T-cell proliferation, and tumor cell lysis with a favorable safety profile.

Jul 1, 2019 · Abstract. Purpose: Delta-like protein 3 (DLL3) is being developed as a predictive biomarker to identify small cell lung cancer (SCLC) patients for

May 5, 2020 · Request PDF | Delta‐Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma | Purpose: Delta-like protein 3 (DLL3) is being developed as a predictive biomarker …

May 5, 2020 · It was found that DLL3 overexpression is very common in MCC by immunohistochemistry and significantly associated with Merkel cell polyomavirus expression. …